Investigation of the expression levels of efflux Pumps in fluconazole-resistant Candida albicans isolates;Flukonazole Dirençli Candida albicans izolatlarinda Atim Pompa Ekspresyonlarinin Araştirilmasi

Mikrobiyoloji Bulteni

Volumn 48, Issue 2, 2014, Pages 325-334

  Gülat, Sinem ^a   Doluca DERELi, Mine ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Candida albicans; Efflux pumps; Fluconazole resistance

Indexed keywords

ANTIFUNGAL AGENT; CARRIER PROTEIN; CDR1 PROTEIN, CANDIDA ALBICANS; FLUCONAZOLE; FUNGAL PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; P-GLYCOPROTEIN;

EID: 84901443075     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: 10.5578/mb.7213     Document Type: Article

References (20)

1. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11 (2): 142-51.
2. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nihon Ishinkin Gakkai Zasshi 2007; 48(1): 1-12. (Pubitemid 46280129)
3. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008; 12(1): 204-12.
4. Erdem I, Ozgultekin A, Inan AS, et al. Bloodstream infections in a medical-surgical intensive care unit: incidence, aetiology, antimicrobial resistance patterns of gram-positive and gram-negative bacteria. Clin Microbiol Infect 2009; 15(10): 943-6.
5. Pfaller MA, Diekema, DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20(1): 133-63. (Pubitemid 46167771)
6. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48(5): 503-35.
7. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2(2): 73-85. (Pubitemid 36114141)
8. Perea S, López-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45(10): 2676-84. (Pubitemid 32906656)
9. Manastir L, Ergon MC, Yucesoy M. Investigation of mutations in Erg11 gene of fluconazole resistant Candida albicans isolates from Turkish hospitals. Mycoses 2011; 54(2): 99-104.
10. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39(11): 2378-86.
11. rd ed. CLSI Document M27-A3, 2008. CLSI Wayne, PA.
12. Pfaller MA, Andes D, Diekema DJ, Espinel-lngroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13(6): 180-95.
13. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones, RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011; 69(1): 45-50.
14. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46(6): 1704-13. (Pubitemid 34535186)
15. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh, TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. Clin Microbiol 2000; 38(4): 1563-8. (Pubitemid 30216690)
16. Vandenbossche I, Vaneechoutte M, Vandevenne M, De Baere T, Verschraegen C. Susceptibility testing of fluconazole by the NCCLS broth macrodilution method. E-test, and disk diffusion for application in the routine laboratory. J Clin Microbiol 2002; 40(3): 918-21. (Pubitemid 34208645)
17. Sanglard D, Ischer F, Marchetti O, Enteriza J, Bille J. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 2003; 48(4): 959-76. (Pubitemid 36628262)
18. Frade JP, Warnock DW, Arthington-Skaggs BA. Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization. J Clin Microbiol 2004; 42(5): 2085-93. (Pubitemid 38637827)
19. Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53(2): 217-24. (Pubitemid 38239953)
20. Chen LM, Xu YH, Zhou CL, Zhao J, Li CY, Wang R. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. J Int Med Res 2010; 38(2): 536-45.